(AOF) – Mauna Kea Technologies publishes a turnover of 10.5 million euros in 2023, an increase of 42% compared to 2022. The inventor of Cellvizio, a multidisciplinary platform for confocal laser endomicroscopy using miniprobe and by needle highlights the record growth in sales of PPU (pay-as-you-go program) which represented 63% of sales in the fourth quarter: this growth is 109% in the 4th quarter of 2023, and 57% over the year.
“This model provides greater stability with recurring and regular revenue, provides access to a significant volume of patients and generates significant operational leverage as system usage increases,” the company emphasizes.
“For the year 2023, growth was mainly driven by the United States and the contribution of the joint venture with Tasly,” underlines Mauna Kea.
“With a promising pipeline of new partnerships and continued support from the international medical community, I am optimistic about the future achievements this new year has in store for us,” says CEO Sacha Loiseau.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
